Dr. Kuriakose is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
343 Oyster Point Blvd
suite 200
South San Francisco, CA 94080Phone+1 469-996-5189
Education & Training
- Memorial Sloan Kettering Cancer CenterMD, Research Fellow, 2011 - 2013
- Weill Cornell Medicine2010 - 2013
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2006 - 2009
- Stony Brook University Health Sciences Center School of MedicineClass of 2006
Certifications & Licensure
- TX State Medical License 2008 - 2025
- NY State Medical License 2010 - 2016
Clinical Trials
- Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis Start of enrollment: 2020 Jul 03
Publications & Presentations
PubMed
- 53 citationsDose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.Sébastien Jeay, Stephane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A. Chapeau
Cancer Research. 2018-11-01 - 34 citationsReal-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practicesSundar Jagannath, Anuja Roy, Jonathan Kish, Orsolya Lunacsek, Michael Eaddy
Expert Review of Hematology. 2016-06-16 - 6 citationsEstimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.Lisa M. Bloudek, Anuja Roy, Jonathan Kish, David S. Siegel, Sundar Jagannath
Journal of Managed Care & Specialty Pharmacy. 2016-07-26
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: